Japan plans to revise its guidelines on the drone delivery of medicines later this month, which would mark the first revision since they were established two years ago. Service providers are closely watching how they will be revised, with calls…
HOME > ORGANIZATION
ORGANIZATION
- Drug Damage Watchdog Calls for Temporary Suspension of Lagevrio Use
April 6, 2022
- JPMA Chief Sees Free Pricing Proposal as Catalyst for Active Reform Debate
April 5, 2022
- Stop Avigan Stockpiling, Revoke Flu Approval: Drug Damage Watchdog
April 5, 2022
- JPMA to Push Innovation Cycle, Ponder Next-Gen Pricing System: FY2022 Project Plan
April 5, 2022
- Policy Veterans’ Group Proposes Free Pricing, Chuikyo Re-Pricing Few Years Later
April 4, 2022
- Generic Use Rate Treads Water at 79.3% in October-December: JGA
April 4, 2022
- FPMAJ Poll Finds 65% Self-Inspection Rate for “Stable Supply Medicines”
March 28, 2022
- FPMAJ Hammers Out FY2022 Project Plans, Revs Up for Off-Year Revision Debate
March 28, 2022
- FPMAJ Begins Survey on Risk of Mineral Resource Shortages amid Ukraine War
March 28, 2022
- JGA to Employ 3rd Party Auditor on Trial Basis to Ensure Manufacturing Compliance
March 28, 2022
- Shipment Curbs Lifted for Only 49 Products by End of 2021 after MHLW Request: FPMAJ Survey
March 25, 2022
- FPMAJ Launches Taskforce to Conduct Supply Surveys for 130 APIs
March 25, 2022
- Number of MSLs Tops 1,000 in FY2021, Up 50% in 2 Years; Lack of Talent an Obstacle to Further Growth: JAPhMed
March 22, 2022
- FPMAJ Should Take Lead to Address Drug Supply Issues: JMA Chief
March 17, 2022
- Realistic Approach Should Be Taken for Supply Chain Surveys: JPMA Economic Security Taskforce
March 15, 2022
- Japan Drug Makers Launch Digital Health Advocacy Group, Mitsubishi Tanabe Exec Serves as Head
March 15, 2022
- Switch to Original Drugs Up Nearly 5-Fold YOY in 6-Month Period from August 2021: NPhA Survey
March 15, 2022
- API Import Costs from Europe Surging amid Russian Airspace Closures
March 15, 2022
- List of 180 Needed Drugs Compiled in Europe-Led Drive to Support Ukraine
March 14, 2022
- Therapeutic Value of Kampo Medicines for COVID-19 Being Examined
March 11, 2022
ページ
The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…